Perimenopause Myths — Debunked

The average age of menopause in India is 46–47, meaning perimenopause commonly begins in the early-to-mid 40s or even the late 30s. Waiting until 50 to consider a diagnosis means many women go unrecognised for years. Any woman over 40 experiencing irregular periods alongside other symptoms — sleep disruption, mood changes, hot flashes — should discuss perimenopause with a doctor. Symptoms, not a birthday, are the diagnostic signal.

Over 30 distinct symptoms are associated with hormonal changes during perimenopause. These include brain fog, joint pain, anxiety, heart palpitations, disrupted sleep, mood swings, low libido, dry skin, hair thinning, and urinary urgency. Many women — particularly South Asian women — experience fewer vasomotor symptoms like hot flashes but still have significant hormonal disruption. Focusing only on hot flashes means many women are never assessed correctly.

Perimenopause symptoms are driven by falling and fluctuating oestrogen and progesterone — real hormonal changes with measurable effects on the brain, bones, cardiovascular system, and metabolism. Oestrogen regulates serotonin and dopamine production; its instability directly causes mood symptoms. Progesterone has GABAergic (calming) effects; its early decline disrupts sleep and amplifies anxiety. Telling a woman her symptoms are "just stress" is not a clinical assessment — it is a dismissal that delays care.

The absolute risk increase from combined HRT is small and varies considerably depending on the type of hormones used, duration of use, and individual history. Transdermal oestrogen with micronised progesterone carries a more favourable safety profile than older oral formulations with synthetic progestogens. The 2002 WHI study that caused widespread panic about HRT was later found to have significant methodological limitations, including an older study population with pre-existing conditions. A gynaecologist can assess your individual risk-benefit balance — for many women, the benefits of HRT clearly outweigh the risks.

FSH and oestradiol levels fluctuate dramatically from week to week during perimenopause. A single blood test showing normal results does not rule out perimenopause. NICE guidelines (NG23) explicitly state that routine blood tests should not be used to diagnose perimenopause in women over 45 with classic symptoms — because the test is unreliable in this context. Diagnosis is clinical: based on age, symptom pattern, and menstrual history. Relying on a single blood test often leads to years of unnecessary delay.

For many women, symptoms actually intensify in the one to two years immediately following the final period. This is because oestrogen continues to settle at its new low level, and the body is still adjusting. Hot flashes, sleep disruption, and mood changes can persist for several years into postmenopause. Vaginal and urinary symptoms often worsen over time without treatment. The end of periods is a milestone, not a cure.

Phytoestrogens in soya have modest evidence for reducing hot flash frequency in some women — the effect is variable and not universal. Ashwagandha has reasonable evidence for stress and cortisol reduction, which can be a useful adjunct. Shatavari has very limited clinical evidence specifically for perimenopause symptoms. Importantly, no herbal remedy replaces oestrogen for protecting bone density, preventing cardiovascular changes, or treating moderate-to-severe vasomotor symptoms. Herbal options can complement a broader plan, but they are not equivalent to clinical treatment.

Hormonal shifts during perimenopause redistribute fat toward the abdomen and reduce muscle mass — but significant total weight gain is not inevitable. Protein intake of 1.2–1.6 g per kg of body weight per day helps preserve muscle during this transition. Strength training (weights, resistance bands) is the most effective form of exercise for maintaining body composition at this life stage. Sleep quality also directly affects hunger hormones and fat storage. Lifestyle choices have a meaningful influence on outcomes — this is not a fixed trajectory.

Declining oestrogen reduces vaginal lubrication, tissue elasticity, and sensitivity. Declining testosterone — which women also produce — reduces sexual desire directly. These are physiological changes with medical solutions: vaginal oestrogen cream or pessaries (effective, safe, and locally acting), quality lubricants, pelvic floor physiotherapy, and in appropriate cases, testosterone therapy. Attributing low libido entirely to the relationship — without considering the hormonal component — means the underlying cause goes untreated. A gynaecologist can assess all contributing factors.

Perimenopause is defined by irregular periods — not their absence. During most of perimenopause, periods continue but change in character: they may become shorter or longer, heavier or lighter, more or less frequent. The absence of periods for 12 consecutive months marks the end of perimenopause (menopause), not its beginning. Most women have periods throughout the majority of their perimenopausal years. Irregular cycles alongside other symptoms are the signal, not absent cycles.

Cognitive symptoms during perimenopause — word-finding difficulty, forgetfulness, reduced concentration, mental slowness — are common and linked to oestrogen fluctuations affecting neurotransmitter systems including serotonin, acetylcholine, and glutamate. These symptoms are typically temporary and improve after the menopause transition as hormones stabilise. They are not the same as dementia. If symptoms are severe, rapidly worsening, or involve other concerning features, a doctor can investigate other causes — but for most women in perimenopause, cognitive symptoms are hormonal, not neurodegenerative.

"Natural" does not mean "no treatment needed." Indian women reach menopause at an average age 2–3 years earlier than Western women, have lower baseline bone density, and have very high rates of vitamin D deficiency — all factors that make bone loss and cardiovascular changes during this transition particularly significant. Untreated symptoms also affect work performance, relationships, and mental health. Stigma around discussing menopause in India is a healthcare gap, not a cultural advantage. Women deserve the same access to accurate information and treatment options as anyone else.